Goldman Sachs
VYNE icon

Goldman Sachs’s VYNE Therapeutics VYNE Stock Holding History

Goldman Sachs’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,428
Closed -$118K – 6931
2021
Q4 		$118K Buy
6,428
+4,092
+175% +$87.8K ﹤0.01% 6088
2021
Q3 		$58K Buy
2,336
+114
+5% +$4.42K ﹤0.01% 6015
2021
Q2 		$141K Sell
2,222
-293
-12% -$23.2K ﹤0.01% 5863
2021
Q1 		$310K Buy
2,515
+76
+3% +$11K ﹤0.01% 5411
2020
Q4 		$278K Buy
2,439
+1,171
+92% +$147K ﹤0.01% 4927
2020
Q3 		$151K Sell
1,268
-153
-11% -$17.9K ﹤0.01% 5001
2020
Q2 		$177K Buy
1,421
+640
+82% +$86.7K ﹤0.01% 4833
2020
Q1 		$151K Sell
781
-15
-2% -$4.71K ﹤0.01% 4805
2019
Q4 		$266K Buy
796
+278
+54% +$92.7K ﹤0.01% 4793
2019
Q3 		$167K Sell
518
-34
-6% -$11K ﹤0.01% 4864
2019
Q2 		$238K Buy
552
+19
+4% +$9.4K ﹤0.01% 4711
2019
Q1 		$301K Buy
533
+34
+7% +$16.3K ﹤0.01% 4632
2018
Q4 		$148K Buy
499
+92
+23% +$41.2K ﹤0.01% 4911
2018
Q3 		$288K Buy
407
+205
+101% +$127K ﹤0.01% 4743
2018
Q2 		$118K Buy
+202
New +$157K ﹤0.01% 5166

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return

Goldman Sachs's VYNE Position: Q1 2022 in Review

Goldman Sachs sold out of VYNE Therapeutics (VYNE) in Q1 2022, closing a stake of 6,428 shares — an estimated $118K sold.

Goldman Sachs first reported a position in VYNE in Q2 2018 and held it in 15 quarters. The position peaked at $310K in Q1 2021. 44 funds tracked by Wall St. Rank hold VYNE as of Q1 2022.

  • Goldman Sachs reported no remaining VYNE Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Goldman Sachs sold 6,428 VYNE Therapeutics shares in Q1 2022, an estimated $118K.
  • Goldman Sachs first reported a position in VYNE Therapeutics in Q2 2018 and held it in 15 quarters.
  • Goldman Sachs's VYNE Therapeutics position peaked at $310K in Q1 2021.
  • 44 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2022.

Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.